Title: Effects of Nesiritide in Patients with Acute Decompensated Heart Failure – A Review
Authors: Rohini.S, T.A. Naufal Rizwan
DOI: http://dx.doi.org/10.18535/jmscr/v4i8.72
Abstract
Acute decompensated heart failure is a major health problem that is associated with several million hospitalizations worldwide each year. [1] In such patients, the predominant symptoms are dyspnea and fatigue which are associated with pulmonary venous congestion and low cardiac output. [2, 3] The primary goal of therapy is the rapid relief of these symptoms. Nesiritide, an intravenous (IV) form of human B-type natriuretic peptide is the first in a new pharmacologicclass of drug for treatment of decompensated congestive heart failure (CHF). Nesiritide, a recombinant B - type natriuretic peptide (BNP) with vasodilatory properties, [4-7] was approved in United States in 2001 for its use in patients with acute heart failure due to its ability to reduce pulmonary-capillary wedge pressure and improve dyspnea. Nesiritide is also well established as an agent for improving hemodynamics in patients with acute heart failure. Compared with other agents used in treatment of acute decompensated heart failure (ADHF), nesiritide is considered to be safer than inotropic agents such as dobutamine and milrinone. The ove all effects of nesiritide in patients associated with acute decompensated heartfailure is reviewed.
KEY WORDS: Acute decompensated heart failure, Dobutamine, Hemodynamics, Milrinone, & Nesiritide.
References
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and strokestatistics — 2010 update: a report from the American Heart Association.Circulation 2010; 121(7):e46-e215.
2. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart FailureSurvey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36.
3. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay andshort-term outcomes among Medicare patients hospitalized for heart failure,1993-2006. JAMA 2010;303:2141-7.
4. Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM.Brain natriuretic peptide: effect on left ventricular filling patterns inhealthy subjects. ClinSci (Lond) 1995;88:159-64.
5. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, anatriuretic peptide, in the treatment of decompensated congestive heartfailure. N Engl J Med 2000;343:246-53. [Errata, N Engl J Med2000;343:896, 1504.]
6. Intravenous nesiritide vs nitroglycerin for treatment of decompensatedcongestive heart failure: a randomized controlled trial. JAMA2002;287:1531-40. [Erratum, JAMA 2002;288:577.]
7. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects ofBNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999; 276:H1049-57.
8. American Heart Association, American Stroke Association. Heart Diseaseand Stroke Statistics—2005 Update. Available at: p://www.americanheart.org/download-dable/heart/1105390918119HDSStats2005Update.pdf.Accessed January 13, 2005.
9. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization forcongestive heart failure among Medicare beneficiaries. Arch Intern Med1997;157:99–104.
10. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone onmortality in severe chronic heart failure: The PROMISE Study Research Group.N Engl J Med 1991;325:1468–75
11. Massie BM, Berk MR, Brozena SC, et al. Can further benefitbe achieved byadding flosequinan to patients with congestive heart failure who remainsymptomatic on diuretic, digoxin, and an angiotensin converting enzymeinhibitor? Results of the Flosequinan-ACE inhibitor Trial (FACET). Circulation1993;88:492–501.
12. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebocontrolledstudy of the efficacy of flosequinan in patients with chronic heart failure.Principal Investigators of the REFLECT Study. J Am CollCardiol 1993;22:65–72.
13. Moe GW, Rouleau JL, Charbonneau L, et al. Neurohormonal activation insevere heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J 2000;139:587–95.
14. Joffee MM, Rosenbaum PR. Invited commentary: propensity scores. Am JEpidemiol 1999;150:327–33.
15. Rubin DB. Estimating causal effects from large data sets using propensityscores. Ann Intern Med 1997;127:757–63.
16. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinicalprogression in patients with mild symptoms of heart failure. Circulation1996;94:2800-6.
17. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropicagents. Prog Cardiovasc Dis 1995;38:167-80.
18. Anderson JL, Askins JC, Gilbert EM, Menlove RL, Lutz JR.Occurrence of ventricular arrhythmias in patients receiving acute andchronic infusions of milrinone. Am Heart J 1986;111:466-74.
19. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M.Prevention and reversal of nitrate tolerance in patients with congestiveheart failure. N Engl J Med 1987;317:799-804.
20. Braunwald E, Colucci WS, Grossman W. Clinical aspects of heartfailure. In: Braunwald E, ed. Heart disease: a textbook of cardiovascularmedicine. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:445-70
21. VanKimmenade RR, Januzzi JL, Baggish AL, et al. Amino-terminal probrainna-triuretic peptide, renal function, and outcomes in acute heart failure:redefining the cardiorenal interaction? J Am CollCardiol 2006;48:1621–7.
22. Mahan NG, Blackstone EH, Francis GS, Starling RC III, Young JB, LauerMS. The prognostic value of estimated creatinine clearance alongside functionalcapacity in patients with chronic congestive heart failure. J Am Coll Cardiol2002;40:1106–13.
23. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretoryeffects of human brain natriuretic peptide infusion in patients with congestiveheart failure. Circulation 1996;94:3184–9.
24. DeLemos JA, McGuire DK, Drazner MH.B-type natriuretic peptide incardiovascular disease. Lancet 2003;362:316–22.
25. Aronson D, Burger AJ, Cleland JG, et al. Nesiritide: a review of its use inacute decompensated heart failure. Drugs 2003;63:47–70.
26. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J.Independent association between acute renal failure and mortality followingcardiac surgery. Am J Med. 1998;104:343–348.
27. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility ofusing serial infusions of nesiritide for heart failure in an outpatient setting (fromthe FUSION I Trial). Am J Cardiol 2004;94:595- 601
28. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD,Bristow MR, Schrier RW.Systemic hemodynamic, neurohormonal, and renaleffects of a steady-state infusion of human brain natriuretic peptide in patientswith hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44.
29. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C,Chatterjee K. Sustained hemodynamic effects of an infusion of nesiritide(human b-type natriuretic peptide) in heart failure: a randomized, doubleblind,placebo-controlled clinical trial: Natrecor Study Group. J Am CollCardiol.1999;34:155–162
30. Stevenson LW, Colucci WS. Management of patients hospitalized with heart failure. In: Smith TW, ed. Cardiovascular therapeutics. Philadelphia:W.B. Saunders, 1996:199-209.